Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study

被引：0
|
作者：
Ait-Khaled, Mounir [1 ]
Oyee, James [2 ]
Ooi, Adrian Yit Reen [3 ]
Wynne, Brian [4 ]
Maldonado, Andres [5 ]
Jones, Bryn [1 ]
Wang, Tao [6 ]
机构：
[1] ViiV Healthcare, 980 Great West Rd, Brentford TW8 9GS, Middx, England
[2] GSK, Brentford, England
[3] ViiV Healthcare, Singapore, Singapore
[4] ViiV Healthcare, Durham, NC USA
[5] ViiV Healthcare, Wavre, Belgium
[6] GSK, Shanghai, Peoples R China
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 05期
关键词：
dolutegravir/lamivudine; elvitegravir; HIV-1; switch study; virologically suppressed; ANTIRETROVIRAL THERAPY; DISOPROXIL FUMARATE; HIV; DYSLIPIDEMIA; COBICISTAT; LAMIVUDINE; INFECTION; RISK;
D O I：
10.1093/ofid/ofae227
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
TANGO results have established the durable efficacy of dolutegravir/lamivudine in virologically suppressed individuals who switched from 3- or 4-drug tenofovir alafenamide (TAF)-based regimens. In this post hoc subgroup analysis, 144-week efficacy and tolerability of dolutegravir/lamivudine in participants who switched from elvitegravir/cobicistat/emtricitabine/TAF were consistent with the overall switch population.Clinical Trials Registration NCT03446573.
引用
收藏
页数：4
相关论文
共 6 条
  • [1] Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study
    Rolle, Charlotte-Paige
    Castano, Jamie
    Nguyen, Vu
    Hinestrosa, Federico
    Dejesus, Edwin
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
  • [2] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
    Osiyemi, Olayemi
    De Wit, Stephane
    Ajana, Faiza
    Bisshop, Fiona
    Portilla, Joaquin
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Leone, Peter
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    George, Nisha
    Wynne, Brian
    Aboud, Michael
    van Wyk, Jean
    Smith, Kimberly Y.
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (06) : 975 - 986
  • [3] Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
    van Wyk, Jean
    Ajana, Faiza
    Bisshop, Fiona
    De Wit, Stephane
    Osiyemi, Olayemi
    Sogorb, Joaquin Portilla
    Routy, Jean-Pierre
    Wyen, Christoph
    Ait-Khaled, Mounir
    Nascimento, Maria Claudia
    Pappa, Keith A.
    Wang, Ruolan
    Wright, Jonathan
    Tenorio, Allan R.
    Wynne, Brian
    Aboud, Michael
    Gartland, Martin J.
    Smith, Kimberly Y.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (08) : 1920 - 1929
  • [4] Durable Efficacy of Switching From a 3-or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196
    De Wit, Stephane
    Bonnet, Fabrice
    Osiyemi, Olayemi
    Bisshop, Fiona
    Olalla, Julian
    Routy, Jean-Pierre
    Wyen, Christoph
    Moodley, Riya
    Pappa, Keith
    Wang, Ruolan
    Oyee, James
    Saggu, Parminder
    Letang, Emilio
    Wynne, Brian
    Jones, Bryn
    Smith, Kimberly Y.
    Ait-Khaled, Mounir
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (02) : 156 - 160
  • [5] Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
    Post, Frank A.
    Yazdanpanah, Yazdan
    Schembri, Gabriel
    Lazzarin, Adriano
    Reynes, Jacques
    Maggiolo, Franco
    Yan, Mingjin
    Abram, Michael E.
    Tran-Muchowski, Cecilia
    Cheng, Andrew
    Rhee, Martin S.
    HIV CLINICAL TRIALS, 2017, 18 (03): : 135 - 140
  • [6] Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
    Llibre, Josep M.
    Brites, Carlos
    Cheng, Chien-Yu
    Osiyemi, Olayemi
    Galera, Carlos
    Hocqueloux, Laurent
    Maggiolo, Franco
    Degen, Olaf
    Taylor, Stephen
    Blair, Elizabeth
    Man, Choy
    Wynne, Brian
    Oyee, James
    Underwood, Mark
    Curtis, Lloyd
    Bontempo, Gilda
    van Wyk, Jean
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) : 720 - 729
1